These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20064705)

  • 1. Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort.
    Park SY; Cooney RV; Wilkens LR; Murphy SP; Henderson BE; Kolonel LN
    Eur J Cancer; 2010 Mar; 46(5):932-6. PubMed ID: 20064705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum zinc and prostate cancer risk in a nested case-control study: The multiethnic cohort.
    Park SY; Wilkens LR; Morris JS; Henderson BE; Kolonel LN
    Prostate; 2013 Feb; 73(3):261-6. PubMed ID: 22851289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum vitamin D concentration and prostate cancer risk: a nested case-control study.
    Ahn J; Peters U; Albanes D; Purdue MP; Abnet CC; Chatterjee N; Horst RL; Hollis BW; Huang WY; Shikany JM; Hayes RB;
    J Natl Cancer Inst; 2008 Jun; 100(11):796-804. PubMed ID: 18505967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.
    Layne TM; Weinstein SJ; Graubard BI; Ma X; Mayne ST; Albanes D
    Cancer; 2017 Jul; 123(14):2698-2704. PubMed ID: 28369777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer in whites: a nested case-control study in the multiethnic cohort study.
    Kim Y; Franke AA; Shvetsov YB; Wilkens LR; Cooney RV; Lurie G; Maskarinec G; Hernandez BY; Le Marchand L; Henderson BE; Kolonel LN; Goodman MT
    BMC Cancer; 2014 Jan; 14():29. PubMed ID: 24438060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study.
    Woolcott CG; Wilkens LR; Nomura AM; Horst RL; Goodman MT; Murphy SP; Henderson BE; Kolonel LN; Le Marchand L
    Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):130-4. PubMed ID: 20056631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations.
    Haiman CA; Stram DO; Vickers AJ; Wilkens LR; Braun K; Valtonen-André C; Peltola M; Pettersson K; Waters KM; Marchand LL; Kolonel LN; Henderson BE; Lilja H
    J Natl Cancer Inst; 2013 Feb; 105(3):237-43. PubMed ID: 23213189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States).
    Nomura AM; Stemmermann GN; Lee J; Kolonel LN; Chen TC; Turner A; Holick MF
    Cancer Causes Control; 1998 Aug; 9(4):425-32. PubMed ID: 9794175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma 25-hydroxy vitamin D and subsequent prostate cancer risk in a nested Case-Control study in Japan: The JPHC study.
    Sawada N; Inoue M; Iwasaki M; Yamaji T; Shimazu T; Sasazuki S; Tsugane S
    Eur J Clin Nutr; 2017 Jan; 71(1):132-136. PubMed ID: 27759068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Travis RC; Crowe FL; Allen NE; Appleby PN; Roddam AW; Tjønneland A; Olsen A; Linseisen J; Kaaks R; Boeing H; Kröger J; Trichopoulou A; Dilis V; Trichopoulos D; Vineis P; Palli D; Tumino R; Sieri S; Bueno-de-Mesquita HB; van Duijnhoven FJ; Chirlaque MD; Barricarte A; Larrañaga N; González CA; Argüelles MV; Sánchez MJ; Stattin P; Hallmans G; Khaw KT; Bingham S; Rinaldi S; Slimani N; Jenab M; Riboli E; Key TJ
    Am J Epidemiol; 2009 May; 169(10):1223-32. PubMed ID: 19359375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.
    Platz EA; Leitzmann MF; Hollis BW; Willett WC; Giovannucci E
    Cancer Causes Control; 2004 Apr; 15(3):255-65. PubMed ID: 15090720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk.
    Travis RC; Perez-Cornago A; Appleby PN; Albanes D; Joshu CE; Lutsey PL; Mondul AM; Platz EA; Weinstein SJ; Layne TM; Helzlsouer KJ; Visvanathan K; Palli D; Peeters PH; Bueno-de-Mesquita B; Trichopoulou A; Gunter MJ; Tsilidis KK; Sánchez MJ; Olsen A; Brenner H; Schöttker B; Perna L; Holleczek B; Knekt P; Rissanen H; Yeap BB; Flicker L; Almeida OP; Wong YYE; Chan JM; Giovannucci EL; Stampfer MJ; Ursin G; Gislefoss RE; Bjørge T; Meyer HE; Blomhoff R; Tsugane S; Sawada N; English DR; Eyles DW; Heath AK; Williamson EJ; Manjer J; Malm J; Almquist M; Marchand LL; Haiman CA; Wilkens LR; Schenk JM; Tangen CM; Black A; Cook MB; Huang WY; Ziegler RG; Martin RM; Hamdy FC; Donovan JL; Neal DE; Touvier M; Hercberg S; Galan P; Deschasaux M; Key TJ; Allen NE
    Cancer Res; 2019 Jan; 79(1):274-285. PubMed ID: 30425058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk.
    Deschasaux M; Souberbielle JC; Latino-Martel P; Sutton A; Charnaux N; Druesne-Pecollo N; Galan P; Hercberg S; Le Clerc S; Kesse-Guyot E; Ezzedine K; Touvier M
    Br J Nutr; 2016 Jan; 115(2):305-14. PubMed ID: 26568368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP.
    Steck SE; Arab L; Zhang H; Bensen JT; Fontham ET; Johnson CS; Mohler JL; Smith GJ; Su JL; Trump DL; Woloszynska-Read A
    PLoS One; 2015; 10(4):e0125151. PubMed ID: 25919866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating 25-hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer.
    Yuan C; Shui IM; Wilson KM; Stampfer MJ; Mucci LA; Giovannucci EL
    Int J Cancer; 2019 May; 144(10):2401-2407. PubMed ID: 30411792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade.
    Gilbert R; Metcalfe C; Fraser WD; Donovan J; Hamdy F; Neal DE; Lane JA; Martin RM
    Int J Cancer; 2012 Sep; 131(5):1187-96. PubMed ID: 22033893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer.
    Weinstein SJ; Mondul AM; Kopp W; Rager H; Virtamo J; Albanes D
    Int J Cancer; 2013 Jun; 132(12):2940-7. PubMed ID: 23180681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study.
    Shui IM; Mucci LA; Kraft P; Tamimi RM; Lindstrom S; Penney KL; Nimptsch K; Hollis BW; Dupre N; Platz EA; Stampfer MJ; Giovannucci E
    J Natl Cancer Inst; 2012 May; 104(9):690-9. PubMed ID: 22499501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: The Melbourne Collaborative Cohort Study.
    Heath AK; Hodge AM; Ebeling PR; Eyles DW; Kvaskoff D; Buchanan DD; Giles GG; Williamson EJ; English DR
    Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):900-908. PubMed ID: 30842127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer.
    Li H; Stampfer MJ; Hollis JB; Mucci LA; Gaziano JM; Hunter D; Giovannucci EL; Ma J
    PLoS Med; 2007 Mar; 4(3):e103. PubMed ID: 17388667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.